MedTrace Logo

Magnesium Supplementation for Hypomagnesemia in Chronic Kidney Disease

NCT02216877 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2015-04-28

No results posted yet for this study

Summary

Randomized placebo-controlled interventional trial to investigate the effect of oral magnesium supplementation on intracellular magnesium in subjects with chronic kidney disease. We hypothesize that oral magnesium supplementation will increase intracellular magnesium in subjects with chronic kidney disease as well as increase serum magnesium.

Conditions

Interventions

DRUG

Mablet 360 mg

DRUG

Placebo

Sponsors & Collaborators

  • Zealand University Hospital

    lead OTHER

Principal Investigators

  • Iain B Bressendorff, MD · Department of Medicine, Division of Nephrology, Roskilde County Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2015-04-30
Completion
2015-04-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02216877 on ClinicalTrials.gov